FLURAZEPAM HCL'S RESIDUAL (HANGOVER) EFFECTS UPON ACTUAL DRIVING PERFORMANCE

Flurazepam HCl is a relatively old and widely used benzodiazepine hypnotic. The long half-life of its active n-desalkyl metabolite may be responsible for residual ("hangover") effects which extend into the day following ingestion of the recommended therapeutic dose (30 mg). A year-long investigation of flurazepam's residual effect on actual automobile driving performance was undertaken in two parts: an acute experiment and a subchronic experiment. The practical relevance of the results were discussed. The major conclusions were as follows: (1) flurazepam 30 mg impairs driving performance for at least 17 hours following drug intake; (2) flurazepam's residual effect is dose-dependent; and (3) frankly unacceptable impairment can occur in some individuals. The major recommendations were as follows: (1) the recommended flurazepam dose for patients who must operate vehicles on days following night-time drug use should not exceed 15 mg; (2) patients who require a higher flurazepam dosage nightly should refrain from driving for at least a week and preferably longer, after the beginning of therapy; and (3) the occasional use of flurazepam over shorter periods by drivers should be strongly discouraged. (TRRL)

  • Corporate Authors:

    Groningen State Univ /Netherlands

    ,    
  • Authors:
    • O'Hanlon, J F
    • De Vries, A
    • Van Arkel, A
    • Van ARKEL, A
    • Wiethoff, M
    • Meijer, T
  • Publication Date: 1983-6

Media Info

  • Features: Figures; References; Tables;
  • Pagination: 51 p.

Subject/Index Terms

Filing Info

  • Accession Number: 00389019
  • Record Type: Publication
  • Source Agency: Institute for Road Safety Research, SWOV
  • Report/Paper Numbers: Monograph
  • Files: ITRD, TRIS
  • Created Date: Nov 30 1984 12:00AM